Zai Lab discloses $249.9 million private securities offering in SEC Form D
The filing shows all shares already sold to 25 investors, with Leerink Partners serving as placement agent.
SEC filing
6 stories
The filing shows all shares already sold to 25 investors, with Leerink Partners serving as placement agent.
SEC filing
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company priced an 11.34 million ADS private placement at $22.04 per share and released a corporate presentation with fresh DLL3 ADC trial results.
SEC filing